Cargando…

Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment

Detalles Bibliográficos
Autores principales: Jiang, Zhidong, Feng, Bo, Zhang, Yumin, Nie, Tianqing, Liu, Hong, Li, Jia, Su, Haixia, Zhang, Leike, Zang, Yi, Zhou, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575875/
https://www.ncbi.nlm.nih.gov/pubmed/37833245
http://dx.doi.org/10.1038/s41392-023-01665-4
_version_ 1785121004119392256
author Jiang, Zhidong
Feng, Bo
Zhang, Yumin
Nie, Tianqing
Liu, Hong
Li, Jia
Su, Haixia
Zhang, Leike
Zang, Yi
Zhou, Yu
author_facet Jiang, Zhidong
Feng, Bo
Zhang, Yumin
Nie, Tianqing
Liu, Hong
Li, Jia
Su, Haixia
Zhang, Leike
Zang, Yi
Zhou, Yu
author_sort Jiang, Zhidong
collection PubMed
description
format Online
Article
Text
id pubmed-10575875
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105758752023-10-15 Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment Jiang, Zhidong Feng, Bo Zhang, Yumin Nie, Tianqing Liu, Hong Li, Jia Su, Haixia Zhang, Leike Zang, Yi Zhou, Yu Signal Transduct Target Ther Correction Nature Publishing Group UK 2023-10-13 /pmc/articles/PMC10575875/ /pubmed/37833245 http://dx.doi.org/10.1038/s41392-023-01665-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Jiang, Zhidong
Feng, Bo
Zhang, Yumin
Nie, Tianqing
Liu, Hong
Li, Jia
Su, Haixia
Zhang, Leike
Zang, Yi
Zhou, Yu
Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title_full Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title_fullStr Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title_full_unstemmed Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title_short Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
title_sort correction: discovery of novel non-peptidic and non-covalent small-molecule 3cl(pro) inhibitors as potential candidate for covid-19 treatment
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575875/
https://www.ncbi.nlm.nih.gov/pubmed/37833245
http://dx.doi.org/10.1038/s41392-023-01665-4
work_keys_str_mv AT jiangzhidong correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT fengbo correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT zhangyumin correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT nietianqing correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT liuhong correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT lijia correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT suhaixia correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT zhangleike correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT zangyi correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment
AT zhouyu correctiondiscoveryofnovelnonpeptidicandnoncovalentsmallmolecule3clproinhibitorsaspotentialcandidateforcovid19treatment